Home > Pulmonology > ERS 2019 > Best of the Posters > Orvepitant successful in decreasing symptoms of chronic cough

Orvepitant successful in decreasing symptoms of chronic cough

Conference
ERS 2019
Trial
Phase 2, VOLCANO-2

A randomised controlled trial studied the effect of the neurokin-1 receptor antagonist orvepitant on cough frequency and found a meaningful reduction in high frequency coughers [1].

Refractory or unexplained chronic cough is an incapacitating and widespread disease with negative influence on quality of life that is often challenging to treat [2]. Currently, there are no proven therapies for this condition, which is often treated off-label with first-generation antihistamines, antidepressants, and opioids – with mixed results. The phase 2b, multicentre, double-blind, randomised controlled VOLCANO-2 trial involved 315 patients from 55 sites all over North America and the United Kingdom [1]. Every study subject had chronic or unexplained chronic cough. Prerequisite for study inclusion was ≥1 year of cough of unclear origin and/or no treatment response, with an awake frequency of ≥10 coughs per hour [1].

The orvepitant group received either 10 mg, 20 mg...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on